Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors.

导出 OA

翻译打印收藏纠错

作者： Ryul,Kim ^[1] ; Bhumsuk,Keam ^[2] ; Sehui,Kim ^[3] ; Miso,Kim ^[4] ; Se Hyun,Kim ^[1] ; Jin Wook,Kim ^[5] ; Yu Jung,Kim ^[6] ; Tae Min,Kim ^[5] ; Yoon Kyung,Jeon ^[1] ; Dong-Wan,Kim ^[7] ; Doo Hyun,Chung ^[7] ; Jong Seok,Lee ^[4] ; Dae Seog,Heo ^[1]

作者单位： Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea. ^[1] Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea. bhumsuk@snu.ac.kr. ^[2] Cancer Research Institute, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03080, South Korea. bhumsuk@snu.ac.kr. ^[3] Department of Pathology, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, South Korea. ^[4] Department of Internal Medicine, Seoul National University Bundang Hospital, 82 Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13620, South Korea. ^[5] Department of Neurosurgery, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, South Korea. ^[6] Cancer Research Institute, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03080, South Korea. ^[7]

关键词 Brain metastasis Immunotherapy Lung cancer PD-1 PD-L1